{"id":22088,"date":"2023-02-14T16:41:00","date_gmt":"2023-02-14T08:41:00","guid":{"rendered":"https:\/\/flcube.com\/?p=22088"},"modified":"2025-01-19T16:44:27","modified_gmt":"2025-01-19T08:44:27","slug":"harbour-biomed-licenses-hbm7008-to-cullinan-oncology-for-us-development","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=22088","title":{"rendered":"Harbour BioMed Licenses HBM7008 to Cullinan Oncology for US Development"},"content":{"rendered":"\n<p>Harbour BioMed (HBM), which operates out of the Netherlands, the United States, and Suzhou, China, has announced a licensing agreement with US firm Cullinan Oncology, Inc. The deal grants Cullinan exclusive rights to develop and commercialize HBM7008 in the United States (including the District of Columbia and Puerto Rico). This strategic partnership aims to accelerate the development and market availability of HBM7008, a promising bispecific antibody (BsAb) for cancer treatment.<\/p>\n\n\n\n<p><strong>Financial Terms of the Agreement<\/strong><br>Under the terms of the agreement, Cullinan will pay Harbour USD 25 million upfront and is committed to up to USD 600 million in milestone payments, alongside 20% of sales in tiered royalties. Cullinan will also shoulder all development and commercialization expenses, while Harbour will retain all rights to the drug outside of the US. This financial structure provides significant potential upside for Harbour while leveraging Cullinan&#8217;s expertise in the US market.<\/p>\n\n\n\n<p><strong>Clinical Development and Rights<\/strong><br>Cullinan also has the right to carry out clinical studies for the drug in the EU and Australia, on the condition that Harbour will retain all rights and share clinical materials. This arrangement allows for efficient and coordinated development efforts across multiple regions, ensuring that the drug&#8217;s potential is fully explored.<\/p>\n\n\n\n<p><strong>HBM7008: Bispecific Antibody for Cancer Treatment<\/strong><br>HBM7008 is a bispecific antibody (BsAb) that simultaneously targets the tumor antigen B7H4 and T cell co-stimulatory molecule 4-1BB. It specifically activates T cells only when binding to B7H4, thereby exerting an anti-tumor effect with improved safety. Currently in Phase I clinical trials, HBM7008 is expected to exert better effects in PD-L1-negative patients or patients resistant to PD-1\/PD-L1 immunotherapy drugs. This makes HBM7008 a potentially valuable addition to the cancer treatment landscape, particularly for patients who do not respond to existing therapies.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Harbour BioMed (HBM), which operates out of the Netherlands, the United States, and Suzhou, China,&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[16,2537,190,28,2790],"class_list":["post-22088","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-cancer","tag-cullinan-oncology","tag-harbour-biomed","tag-multi-specific-antibodies","tag-t-cell-engager"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Harbour BioMed Licenses HBM7008 to Cullinan Oncology for US Development - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Harbour BioMed (HBM), which operates out of the Netherlands, the United States, and Suzhou, China, has announced a licensing agreement with US firm Cullinan Oncology, Inc. The deal grants Cullinan exclusive rights to develop and commercialize HBM7008 in the United States (including the District of Columbia and Puerto Rico). This strategic partnership aims to accelerate the development and market availability of HBM7008, a promising bispecific antibody (BsAb) for cancer treatment.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=22088\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Harbour BioMed Licenses HBM7008 to Cullinan Oncology for US Development\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=22088\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-02-14T08:41:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-19T08:44:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22088#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22088\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Harbour BioMed Licenses HBM7008 to Cullinan Oncology for US Development\",\"datePublished\":\"2023-02-14T08:41:00+00:00\",\"dateModified\":\"2025-01-19T08:44:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22088\"},\"wordCount\":308,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Cancer\",\"Cullinan Oncology\",\"Harbour BioMed\",\"Multi-specific antibodies\",\"T cell engager\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=22088#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22088\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=22088\",\"name\":\"Harbour BioMed Licenses HBM7008 to Cullinan Oncology for US Development - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-02-14T08:41:00+00:00\",\"dateModified\":\"2025-01-19T08:44:27+00:00\",\"description\":\"Harbour BioMed (HBM), which operates out of the Netherlands, the United States, and Suzhou, China, has announced a licensing agreement with US firm Cullinan Oncology, Inc. The deal grants Cullinan exclusive rights to develop and commercialize HBM7008 in the United States (including the District of Columbia and Puerto Rico). This strategic partnership aims to accelerate the development and market availability of HBM7008, a promising bispecific antibody (BsAb) for cancer treatment.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22088#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=22088\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22088#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Harbour BioMed Licenses HBM7008 to Cullinan Oncology for US Development\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Harbour BioMed Licenses HBM7008 to Cullinan Oncology for US Development - Insight, China&#039;s Pharmaceutical Industry","description":"Harbour BioMed (HBM), which operates out of the Netherlands, the United States, and Suzhou, China, has announced a licensing agreement with US firm Cullinan Oncology, Inc. The deal grants Cullinan exclusive rights to develop and commercialize HBM7008 in the United States (including the District of Columbia and Puerto Rico). This strategic partnership aims to accelerate the development and market availability of HBM7008, a promising bispecific antibody (BsAb) for cancer treatment.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=22088","og_locale":"en_US","og_type":"article","og_title":"Harbour BioMed Licenses HBM7008 to Cullinan Oncology for US Development","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=22088","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-02-14T08:41:00+00:00","article_modified_time":"2025-01-19T08:44:27+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=22088#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=22088"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Harbour BioMed Licenses HBM7008 to Cullinan Oncology for US Development","datePublished":"2023-02-14T08:41:00+00:00","dateModified":"2025-01-19T08:44:27+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=22088"},"wordCount":308,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Cancer","Cullinan Oncology","Harbour BioMed","Multi-specific antibodies","T cell engager"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=22088#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=22088","url":"https:\/\/flcube.com\/?p=22088","name":"Harbour BioMed Licenses HBM7008 to Cullinan Oncology for US Development - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-02-14T08:41:00+00:00","dateModified":"2025-01-19T08:44:27+00:00","description":"Harbour BioMed (HBM), which operates out of the Netherlands, the United States, and Suzhou, China, has announced a licensing agreement with US firm Cullinan Oncology, Inc. The deal grants Cullinan exclusive rights to develop and commercialize HBM7008 in the United States (including the District of Columbia and Puerto Rico). This strategic partnership aims to accelerate the development and market availability of HBM7008, a promising bispecific antibody (BsAb) for cancer treatment.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=22088#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=22088"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=22088#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Harbour BioMed Licenses HBM7008 to Cullinan Oncology for US Development"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/22088","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=22088"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/22088\/revisions"}],"predecessor-version":[{"id":22089,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/22088\/revisions\/22089"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=22088"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=22088"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=22088"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}